Joseph Galli, Chairman of the Board and Chief Executive Officer, Haemacure
Mr. Joseph Galli is founder and managing partner of PENTOR Alliance Corporation and PENTOR Capital Corp. Over the past 25 years, Mr. Galli has completed dozens of restructuring, due diligence, and acquisition mandates in numerous industries on behalf of several private equity and venture capital firms and industry clients. He has directed over 200 conferences, seminars, and workshops, has been a director of several private and public organizations, and is also an investor in a number of early stage public companies. Prior to forming the PENTOR group of companies, Mr. Galli was a consultant with Ernst & Whinney (now KPMG International), where he successfully raised millions of dollars and gained expertise in insolvency, bankruptcy, and corporate restructuring.
Joseph A. Akers, B.Sc., MBA
Mr. Joseph Akers started his career in the healthcare industry by joining Cutter Laboratories in California in 1970, which later became Bayer AG’s (BAY-NYSE) Biological Products division. Over the years, Mr. Akers held various senior and executive positions in corporate finance and administration at Bayer in Europe and the U.S. In 1999, he was appointed executive vice president and chief administrative and financial officer of Bayer Corporation (the U.S. subsidiary of Bayer AG). In 2004, he was appointed president of Bayer HealthCare’s Hematology/Cardiology business unit, from which he retired in 2007.
Pierre Alary, CA, Senior Vice-President and Chief Financial Officer, Bombardier Inc.
Mr. Pierre Alary, a CA, spent 20 years at Ernst & Young from 1978 to 1998. During his last 10 years as a senior partner, he was responsible for providing audit and consulting services to major manufacturing and high-tech companies. He also became involved in the biotechnology industry and was active in the development of the Ernst & Young biotechnology practice in Québec. Mr. Alary co-founded the Québec Biotechnology Association, which later became BIOQuébec. Mr. Alary joined Bombardier, Inc. (BBD.BTSX) in 1998 as vice president, finance for the rail transportation side of the business, Bombardier Transportation. In Berlin, he was responsible for the finance aspect of the acquisition and the integration of Adtranz, acquired by Bombardier in 2001 from DaimlerChrysler AG (now Daimler AG [DAI-NYSE]). As a member of the Management and Executive Committees, he was responsible for finance worldwide for the Bombardier Transportation group. In November 2002, Mr. Alary was promoted to vice president, finance for Bombardier Inc. and, in February 2003, to senior vice president and interim chief financial officer (CFO). Since June 2003, he has held the position of senior vice president and CFO of Bombardier Inc., with responsibility for all lines of the business.
Paul Baehr, Chairman, Chief Executive Officer and President, IBEX Technologies, Inc.
Mr. Paul Baehr has served as chairman, president, and CEO of IBEX Technologies Inc. (IBT-TSX) since it became public in 1995. Mr. Baehr’s business career began in product management with The Procter & Gamble Company (PG-NYSE). He joined Ciba-Geigy Canada Ltd. (now Novartis AG [NVS-NYSE]) to lead the Consumer Products division and subsequently became general manager of Ciba-Geigy’s Canadian Pharmaceuticals division. In 1980, Mr. Baehr transferred to Ciba-Geigy’s U.S. division as senior vice president of marketing. He joined the Eastman Kodak Company (EK-NYSE) in 1985 as corporate vice president, pharmaceuticals to lead the pharmaceutical diversification program. Mr. Baehr became executive vice president, pharmaceuticals at Sterling-Winthrop, Inc. in New York, when Kodak acquired Sterling-Winthrop in 1988. He has served on the boards of a number of U.S. and Canadian biotechnology companies and on the boards of St. Barnabas Hospital in Livingston, New Jersey, and the Fox Chase Cancer Center in Philadelphia, Pennsylvania. He also served on the Board of the National Pharmaceutical Council in Washington, D.C.
Reinaldo M. Diaz, Managing Director, Celtic Pharma Management, L.P.
Mr. Diaz has over 25 years of experience in the biopharmaceutical industry. He currently serves as a Managing Director of Celtic Pharma Management, L.P. a global equity firm focused on the pharmaceutical industry. Prior to joining Celtic Pharma, Mr. Diaz was Managing Member and Co-Founder of D&A Capital Management, LLC ("D&A Capital"), a firm focused on asset management and providing advisory services to companies in the healthcare sector, particularly biopharmaceutical companies. From 1993 to 1996, Reinaldo was Managing Director and Head of the Healthcare group at Schroder Wertheim & Co., Inc. In that capacity, he was responsible for establishing and expanding Schroder Wertheim's investment banking presence in the healthcare industry. From 1981 to 1993, Reinaldo was with PaineWebber, Inc. During his tenure at PaineWebber, he was a key member of the PaineWebber Healthcare Investment Banking Group and of PaineWebber Development Corporation. He became President of PaineWebber Development Corporation in 1990, having been a managing director prior to that time.
Wayne G. Johnson, Chairman and CEO, BioVentures, Inc.
Mr. Wayne Johnson graduated from The Creighton University in 1965 with a B.S.M.T. and has since accrued over 30 years of experience in the medical and blood products industries. He held senior management and executive positions with Johnson & Johnson (JNJ-NYSE), the Warner-Lambert Company (now Pfizer Inc. [PFE-NYSE]), and Bayer in operations, marketing, and business development. In 1991, Mr. Johnson founded BioVentures, Inc., a biomedical venture capital and business development company, and has since arranged for and provided financing and advice to numerous companies in various stages of development. He also served as a director of many private and public companies. Mr. Johnson is a co-founder and chairman of Canadian Plasma Products Inc.
Thomas J. Lynch, Senior Vice-President Compliance, Regulatory Affairs and Public Policy, Talecris Biotherapeutics
From 2003-2005, Dr. Lynch served as Vice President, Regulatory Affairs and Quality Assurance at CryoLife, Inc., a manufacturer of medical tissues, heart valves and oncology drugs, where he was responsible for, among other things, ensuring compliance with domestic and international laws and regulations governing the design, manufacture, and distribution of medical devices, biological products and human tissues. Prior to joining CryoLife, Dr. Lynch served as Senior Vice President, Regulatory Affairs and Quality Assurance at Clearant Inc., a biotechnology company developing pathogen inactivation technology for the biological products market. Dr. Lynch also served as Deputy Director, Division of Hematology, Office of Blood Research and Review, Center for Biologics Evaluation and Research (CBER) at the FDA, a forty five-member Division engaged in research and regulatory activities related to investigational new drugs and licensing of transfusable blood components, purified plasma-derived proteins and their recombinant analogues. Prior to joinning the FDA, Dr. Lynch has accrued about 15 years of experience as a research scientist in various capacities in the public, academic and private sectors; his primary scientific interests have been in the areas of protein chemistry and enzymology. Dr. Lynch received his Bachelor of Arts degree in biology from American International College and his Masters in biology from Clark University. Dr. Lynch received his Ph.D. in biology from Wayne State University and his J.D. from Georgetown University Law Center, where he graduated cum laude.